Schering Corporation

Hergen Spits

Di-Hwei Hsu

Albert Zlotnik

Maureen C Howard

Anne O'Garra

Hiroshi Ishida

Rene De Waal Malefyt

Kevin W Moore

Rene De Malefyt

A method is provided for toting a B cell mediated autoimmune disorder comprising administering an effective amount of an interleukin-10 antagonist.

Use of an interleukin-10 antagonist to treat a B cell mediated

A method is provided for reducing an inflammatory response in a mammal comprising administering to a mammal at risk of developing or afflicted with an inflammatory response characterized by substantially elevated levels of IL-1.alpha., IL-1.beta., IL-6, IL-8 and TNF.alpha., an amount of IL-10 effective to substantially lower the levels of such cytokines.

Use of interleukin-10 analogs for antagonists to treat endotoxin- or

A method is provided for treating septic shock or toxic shock that comprises administering an effective amount of interleukin-10.

Use of interleukin-10 (IL-10) to treat endotoxin- or

A method is provided for using interleukin-10 in adoptive immunotherapy of cancer. A population of tumor-infiltrating lymphocytes (TILs) are expanded in culture in the presence of interleukin-2 (IL-2) and interleukin-10 (IL-10). After administration of the TILs to a patient, effective amounts of both IL-2 and IL-10 are administered to enhance the tumor cell cytoxicity of the TILs and to reduce side effects caused by IL-2-induced cytokine production in the TILs and other cells of the patient.

Growing community of inventors

Badhoevedorp, Netherlands

Hergen Spits